|
1) Aoki T, Hashimoto N, Matsutani M. Management of glioblastoma. Expert Opin Pharmacother. 2007; 8: 3133-46
|
|
|
|
2) Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995; 345: 1008-12
|
|
|
|
|
|
3) Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 2003; 5: 79-88
|
|
|
|
|
|
4) Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343: 1350-4
|
|
|
|
|
|
5) Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003
|
|
|
|
|
|
6) Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 1004-11
|
|
|
|
|
|
7) Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999; 17: 2604-13
|
|
|
|
|
|
8) Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004; 62: 2113-5
|
|
|
|
|
|
9) Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006; 95: 1155-60
|
|
|
|
|
|
10) Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 4363-7
|
|
|
|
|
|
11) Vera K, Djafari L, Faivre S, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol. 2004; 15: 161-71
|
|
|
|
|
|
12) Spiro TP, Liu L, Majka S, et al. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001; 7: 2309-17
|
|
|
|
|
|
13) Raizer JJ, Malkin MG, Kleber M, et al. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro Oncol. 2004; 6: 247-52
|
|
|
|
|
|
14) Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006; 24: 4412-7
|
|
|
|
|
|
15) Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004; 60: 353-7
|
|
|
|
|
|
16) Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005; 61: 1454-9
|
|
|
|
|
|
17) Spence AM, Peterson RA, Scharnhorst JD, et al. Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol. 2004; 70: 91-5
|
|
|
|
|
|
18) Natsume A, Ishii D, Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005; 65: 7573-9
|
|
|
|
|
|
19) Balana C, Lopez-Pousa A, Berrocal A, et al. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol. 2004; 70: 359-69
|
|
|
|
|
|
20) Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005; 23: 7178-87
|
|
|
|
|
|
21) Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002; 20: 1383-8
|
|
|
|
|
|
22) Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005; 23: 9359-68
|
|
|
|
|
|
23) Fine HA, Kim L, Royce C, et al. Thornton Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas 2005 ASCO Annual Meeting Proceedings. ASCO Meeting Abstracts. 2005; 23: 1504
|
|
|
|
|
|
24) Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-9
|
|
|
|
|
|
25) Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-8
|
|
|
|
|
|
26) Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991; 9: 860-4
|
|
|
|
|
|
27) Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol. 2009; 92: 45-8
|
|
|
|
|
|
28) Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003; 65: 27-35
|
|
|
|
|
|
29) Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005; 102: 267-75
|
|
|
|
|
|
30) Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65: 3-13
|
|
|
|
|
|
31) Wasserfallen JB, Ostermann S, Leyvraz S, et al. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol. 2005; 7: 189-95
|
|
|
|
|
|
32) Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008; 26: 1012-3
|
|
|
|
|
|
33) Aoki T, Mizutani T, Nojima K, et al. Phase II Study of Ifosfamide, Carboplatin and Etoposide for Patients with Glioblastoma at first relapse. J Neurosurg. 2009 Jun 19. [Epub ahead of print]
|
|
|
|
|
|
34) Lai A, Nghiemphu P, Green R, et al. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2009: 27: 15s. (suppl; abstr 2000)
|
|
|
|
|
|
35) Wick A, Pascher C, Wick W, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 2009; 256: 734-41
|
|
|
|
|
|
36) Perry JR, Rizek P, Cashnan R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue" approach. Cancer. 2008; 113: 2152-7
|
|
|
|
|